Understanding how trastuzumab deruxtecan works in HER2 positive breast cancer
Spatial Transcriptomic Approach for Revealing the Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.
This study is trying to understand why some people with HER2 positive breast cancer don’t respond to the treatment trastuzumab deruxtecan, to help improve future treatment options.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Sex | Female |
| Sponsor | Samsung Medical Center Academic / other |
| Drugs / interventions | trastuzumab |
| Locations | 1 site (Seoul) |
| Trial ID | NCT06330012 on ClinicalTrials.gov |
What this trial studies
This study utilizes a spatial transcriptomic approach to investigate the mechanisms of resistance to trastuzumab deruxtecan in patients with HER2 positive breast cancer. By analyzing formalin-fixed paraffin-embedded (FFPE) samples from patients who have undergone treatment, the study aims to uncover the biological factors that contribute to treatment resistance. The findings could provide insights into improving therapeutic strategies for this patient population.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with stage IV HER2 positive breast cancer who have been treated with trastuzumab deruxtecan and have available FFPE samples.
Not a fit: Patients with triple-negative breast cancer or hormone receptor positive breast cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to enhanced treatment options for patients with HER2 positive breast cancer by identifying resistance mechanisms.
How similar studies have performed: While the specific approach of this study may be novel, similar studies investigating resistance mechanisms in cancer treatments have shown promise in the past.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * HER2 positive breast cancer * Stage IV disease * Treated with T-Dxd * Available FFPE samples Exclusion Criteria: * TNBC breast cancer * Hormone receptor positive breast cancer * Non-available FFPE samples * Treated except T-Dxd
Where this trial is running
Seoul
- Ji-Yeon Kim — Seoul, South Korea (Recruiting)
Study contacts
- Study coordinator: Ji-Yeon Kim
- Email: jyeon25@skku.edu
- Phone: 82-2-3410-3459
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.